Paine Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

PAIN MCID: PNS012 MIFTS: 63	Paine Syndrome (PAIN) Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Paine Syndrome

MalaCards integrated aliases for Paine Syndrome:

Name: Paine Syndrome ⁵⁷ ¹⁹ ⁷¹

Pain Disorder ¹¹ ⁵³ ¹⁴ ⁷¹

Pain ⁵ ⁴¹ ¹⁶

Microcephaly with Spastic Diplegia ⁵⁷ ¹⁹

Pain Syndrome ¹⁴

Characteristics:

Inheritance:

X-linked ⁵⁷

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

General symptoms and signs

Pain, not elsewhere classified

Pain, unspecified

ICD11: ³³

Diseases of the nervous system

Other disorders of the nervous system

Pain disorders

Other specified pain disorders

Pain disorders, unspecified

External Ids:

Disease Ontology ¹¹ DOID:0060164

OMIM® ⁵⁷ 311400

ICD10 ³¹ R52 R52.9

MedGen ⁴⁰ C1412041

SNOMED-CT via HPO ⁶⁹ 192992007 267581004 271611007 more

EFO ¹⁶ EFO_0003843

ICD11 ³³ 292232825 292232825/other 292232825/unspecified

UMLS ⁷¹ C0391976 C1412041

Sources

Summaries for Paine Syndrome

MedlinePlus: ⁴¹ Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary: Paine Syndrome, also known as pain disorder, is related to paroxysmal extreme pain disorder and indifference to pain, congenital, autosomal recessive. An important gene associated with Paine Syndrome is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Cardiac conduction and G-Beta Gamma Signaling. The drugs Dinoprostone and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include dorsal root ganglion, spinal cord and breast, and related phenotypes are microcephaly and spastic diplegia

GARD: ¹⁹ Mental retardation, microcephaly, spastic diplegia, seizures, and mild aminoaciduria are the principal features. Seemanova syndrome 1 and Paine syndrome are considered as variants of the same entity termed Paine-Seemanova syndrome.

Disease Ontology: ¹¹ A somatoform disorder that involves chronic pain in one or more areas, and is thought to be caused by psychological stress.

More information from OMIM: 311400

Sources

Related Diseases for Paine Syndrome

Diseases in the Chronic Pain family:

Paine Syndrome

Central Pain Syndrome

Diseases related to Paine Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 4315)

#	Related Disease	Score	Top Affiliating Genes
1	paroxysmal extreme pain disorder	32.9	TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
2	indifference to pain, congenital, autosomal recessive	32.9	SCN9A SCN11A SCN10A
3	myofascial pain syndrome	32.7	TRPV1 TAC1 P2RX3 NGF CALCA
4	episodic pain syndrome, familial, 3	32.7	TRPA1 SCN9A SCN3A SCN11A SCN10A
5	episodic pain syndrome, familial, 1	32.7	TRPV1 TRPA1 SCN9A SCN11A SCN10A
6	complex regional pain syndrome	32.6	TRPV1 TRPA1 TAC1 SCN9A SCN11A SCN10A
7	familial episodic pain syndrome	32.6	TRPV1 TRPA1 SCN9A SCN11A SCN10A
8	neuropathy, hereditary sensory and autonomic, type vii	32.6	SCN9A SCN11A
9	episodic pain syndrome, familial, 2	32.5	TRPA1 SCN9A SCN4A SCN3A SCN11A SCN10A
10	reflex sympathetic dystrophy	32.5	TRPV1 TAC1 SCN9A SCN11A NGF CALCA
11	causalgia	32.4	TRPV1 TAC1 SCN9A SCN10A NGF CALCA
12	pain agnosia	32.2	TRPV1 TRPA1 TAC1 SCN9A SCN11A SCN10A
13	glossopharyngeal neuralgia	32.1	TRPV1 TAC1 SCN9A P2RX3 CALCA
14	plantar fasciitis	32.1	TAC1 CALCA
15	hereditary sensory neuropathy	32.0	SCN9A SCN11A NGF
16	neuropathy	32.0	SCN9A SCN11A SCN10A NGF GJB1
17	epicondylitis	32.0	TAC1 COL5A1 CALCA
18	bursitis	31.9	TAC1 CALCA
19	frozen shoulder	31.8	TAC1 CALCA
20	lateral medullary syndrome	31.8	TAC1 CALCA
21	alcoholic neuropathy	31.7	TRPA1 P2RX3
22	acute cystitis	31.6	TRPV1 NGF
23	hirschsprung disease 1	31.6	TAC1 NGF GAL CALCA
24	nerve compression syndrome	31.6	TRPV1 TAC1 NGF CALCA
25	opioid abuse	31.5	TAC1 PNOC OPRM1
26	peripheral nervous system disease	31.5	TRPV1 TRPA1 TAC1 SCN9A SCN4A SCN3A
27	lesion of sciatic nerve	31.5	TRPV1 NGF
28	neuroma	31.5	TRPV1 SCN10A NGF CALCA
29	urethral syndrome	31.5	TAC1 P2RX3 NGF
30	hyperhidrosis, gustatory	31.5	TRPV1 TRPA1 TAC1
31	cluster headache	31.4	PNOC CALCA
32	sodium channelopathy-related small fiber neuropathy	31.4	SCN9A SCN11A SCN10A
33	interval angle-closure glaucoma	31.4	TAC1 CALCA
34	familial hemiplegic migraine	31.4	SCN9A P2RX3 OPRM1 CALCA
35	bowel dysfunction	31.3	TRPV1 TAC1 OPRM1 CALCA
36	chronic pain	31.3	SCN9A P2RX3 OPRM1
37	erythromelalgia	31.3	TRPV1 TRPA1 TAC1 SCN9A SCN4A SCN3A
38	trigeminal neuralgia	31.2	TRPV1 TRPA1 TAC1 SCN9A SCN3A SCN11A
39	mononeuropathy	31.1	TRPV1 TAC1 NGF GJB1 GAL CALCA
40	diabetic polyneuropathy	31.0	TRPV1 TAC1 SCN9A SCN10A NGF CALCA
41	taylor's syndrome	31.0	TAC1 CALCA
42	horner's syndrome	30.9	NGF CALCA
43	migraine with aura	30.8	TAC1 SCN9A OPRM1 CALCA
44	brugada syndrome	30.8	SCN9A SCN4A SCN3A SCN11A SCN10A
45	neurogenic arthropathy	30.7	SCN9A NGF CALCA
46	fibromyalgia	30.6	SCN9A PNOC P2RX3 OPRM1 NGF CALCA
47	overactive bladder syndrome	30.6	P2RX3 NGF
48	chronic cystitis	30.6	TRPV1 TAC1 P2RX3 NGF
49	graves disease 1	30.4	SCN4A CALCA
50	paralytic ileus	30.4	TAC1 CALCA

Graphical network of the top 20 diseases related to Paine Syndrome:

Sources

Symptoms & Phenotypes for Paine Syndrome

Human phenotypes related to Paine Syndrome:

³⁰

#	Description	HPO Source Accession
1	microcephaly ³⁰	HP:0000252
2	spastic diplegia ³⁰	HP:0001264
3	olivopontocerebellar hypoplasia ³⁰	HP:0006955
4	generalized myoclonic seizure ³⁰	HP:0002123

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Head:
microcephaly
hypoplasia of cerebellum, inferior olives and pons

Lab:
variable elevated spinal fluid amino acids

Neuro:
spastic diplegia
myoclonic seizures
absent abdominal reflexes

Clinical features from OMIM®:

311400 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Paine Syndrome:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.1	CALCA GAL GJB1 HFE NGF OAT
2	normal	MP:0002873	10.07	CALCA COL5A1 HFE NGF OAT OPRM1
3	growth/size/body region	MP:0005378	9.97	COL5A1 GAL GJB1 HFE NGF OAT
4	behavior/neurological	MP:0005386	9.91	CALCA GAL GJB1 HFE NGF OAT
5	no phenotypic analysis	MP:0003012	9.87	HFE NGF OPRM1 SCN10A SCN3A TRPA1
6	integument	MP:0010771	9.47	CALCA COL5A1 GAL NGF OAT OPRM1

Sources

Drugs & Therapeutics for Paine Syndrome

Drugs for Paine Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dinoprostone

Approved

Phase 4

363-24-6, 7448-03-5

5280360

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Cycloserine

Approved

Phase 4

68-41-7

6234

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Ethanol

Approved

Phase 4

64-17-5

702

Amitriptyline

Approved

Phase 4

50-48-6

2160

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Cyclobenzaprine

Approved

Phase 4

303-53-7

2895

Naltrexone

Approved, Investigational, Vet_approved

Phase 4

16590-41-3

5360515

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Citalopram

Approved

Phase 4

59729-32-7, 59729-33-8

2771

Doxycycline

Approved, Investigational, Vet_approved

Phase 4

564-25-0

54671203

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Ascorbic acid

Approved, Nutraceutical

Phase 4

50-81-7

54676860 54670067 5785

Vitamin A

Approved, Nutraceutical, Vet_approved

Phase 4

22737-96-8, 68-26-8

5280382 445354

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Mosapride

Investigational

Phase 4

112885-41-3

119584

Dexetimide

Withdrawn

Phase 4

21888-98-2

30843

Trace Elements

Phase 4

Micronutrients

Phase 4

Calciferol

Phase 4

Psychotropic Drugs

Phase 4

Analgesics, Opioid

Phase 4

Anticonvulsants

Phase 4

Dexamethasone 21-phosphate

Phase 4

HIV Protease Inhibitors

Phase 4

Taxane

Phase 4

108169

protease inhibitors

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Vitamins

Phase 4

Antioxidants

Phase 4

Anti-Anxiety Agents

Phase 4

Anti-Ulcer Agents

Phase 4

Antacids

Phase 4

Proton Pump Inhibitors

Phase 4

Serotonin Receptor Agonists

Phase 4

Hypnotics and Sedatives

Phase 4

Antimetabolites

Phase 4

Antitubercular Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Ketorolac Tromethamine

Phase 4

Antidepressive Agents, Tricyclic

Phase 4

Potassium phosphate

Phase 4

abobotulinumtoxinA

Phase 4

Botulinum Toxins, Type A

Phase 4

Interventional clinical trials:

(show top 50) (show all 780)

#	Name	Status	NCT ID	Phase	Drugs
1	CT-guided Ganglion Impar Block for Management of Phantom Rectal Pain Syndrome	Unknown status	NCT03694639	Phase 4
2	The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain	Unknown status	NCT03748290	Phase 4	Pregabalin;Placebo Oral Tablet
3	The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain	Unknown status	NCT01417923	Phase 4	vitamin D
4	A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial	Completed	NCT01903096	Phase 4	Primary Care Treatment As Usual
5	A Multi-Centre Randomised Study Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for Taxane- Associated Pain Syndrome (TAPS) in Breast Cancer Patients (OTT 17-02 REaCT-TAPS)	Completed	NCT03348696	Phase 4	Dexamethasone tapering dose;Dexamethasone physician choice
6	Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study	Completed	NCT02639039	Phase 4	Cortisone Injection
7	A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome	Completed	NCT00663897	Phase 4	lansoprazole;mosapride
8	Effects of Dexmedetomidine as an Adjunctive Analgesic Used in Continuous Thoracic Paravertebral Blocks for Post-thoracotomy Pain Syndrome	Completed	NCT02619513	Phase 4	Dexmedetomidine;Ropivacaine
9	A Prospective, Randomized, Double Blinded, Placebo Controlled Pilot Study Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome	Completed	NCT00663962	Phase 4	Pregabalin;Placebo
10	Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain	Completed	NCT02385266	Phase 4	D-Cycloserine;Placebo (for D-cycloserine)
11	Combined Platelet Rich Plasma Intra-articular Shoulder Injection and Stellate Ganglion Block. A New Technique for Management of Chronic Post-mastectomy Shoulder Pain Syndrome	Completed	NCT03586154	Phase 4	ketamine and bupivacaine injection
12	Prophylactic Administration of Vitamin C in Wrist Fractures; a Randomized Placebo Controlled Multicentre Dose-Finding Study of the Incidence of Complex Regional Pain Syndrome	Completed	NCT00296868	Phase 4	ascorbic acid (vitamin C) versus placebo
13	The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study	Completed	NCT00272532	Phase 4	Thiocolchicoside
14	Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial.	Completed	NCT01250184	Phase 4	Lidocaine injection
15	Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome	Completed	NCT01764464	Phase 4	Gralise®;Placebo
16	Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief	Completed	NCT02265848	Phase 4
17	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions	Completed	NCT00904202	Phase 4	Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
18	Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain	Completed	NCT01067456	Phase 4
19	Restore Claims Characterization Study	Completed	NCT00200122	Phase 4
20	Prevention of Persistent Pain and Opioid Use in Mothers - POMS	Completed	NCT03472521	Phase 4	Gabapentin;Placebo
21	Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial.	Recruiting	NCT04704297	Phase 4	Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.;Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.;Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
22	GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis	Recruiting	NCT05518864	Phase 4
23	Evaluation of the Effect of Dextrose Prolotherapy on Pain and Function in Women With Myofascial Pain Syndrome	Recruiting	NCT04941118	Phase 4	Injection of dextrose, local anesthetic and saline to the myofascial trigger point;Local anesthetic and saline injection to the myofascial trigger point
24	IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial	Recruiting	NCT04313972	Phase 4	low-dose naltrexone;Placebo oral tablet
25	Peripheral Nerve Injections for the Treatment of Upper Extremity Complex Regional Pain Syndrome: A Feasibility Study for a Proposed Randomized Design	Not yet recruiting	NCT04744675	Phase 4	Triamcinolone Acetonide 40mg/mL;Saline Injection
26	Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)	Suspended	NCT00194636	Phase 4
27	Sinusitis and Facial Pain Disorders Anti-Depression Trial	Terminated	NCT00754793	Phase 4	escitalopram;placebo
28	Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study	Terminated	NCT01879930	Phase 4	doxycycline;placebo
29	A Prospective, Open Label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus no Enoxaparin in Subjects With Chest Pain Syndrome and no ECG or Biomarker Abnormalities	Terminated	NCT00518245	Phase 4	enoxaparin
30	Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial	Terminated	NCT00194623	Phase 4	Botulinum Toxin A (Botox)
31	Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III	Terminated	NCT00194597	Phase 4	Viagra (sildenafil citrate)
32	Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial.	Terminated	NCT00628355	Phase 4	lidocaine
33	Using Saline for Myofascial Pain Syndromes (USAMPS)	Terminated	NCT02120261	Phase 4	Normal Saline;Lidocaine Hydrochloride;Triamcinolone acetonide
34	A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment	Withdrawn	NCT00673972	Phase 4
35	Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial	Withdrawn	NCT00863889	Phase 4	Depomedrol injection;Lidocaine, Marcaine
36	Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome	Withdrawn	NCT01689896	Phase 4	Testosterone Gel;Placebo Gel
37	Pilot Study: Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women, an Open Label Study With Dose Escalation	Withdrawn	NCT02981459	Phase 4	Mirabegron
38	Comparative Efficacy of Platelet Rich Plasma Injection and Dry Needling in Management of Trigger Points in Masseter Muscle in Myofascial Pain Syndrome Patients	Unknown status	NCT04286880	Phase 3
39	Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb	Unknown status	NCT01612364	Phase 3
40	A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)	Unknown status	NCT00371033	Phase 3	Pregabalin;Placebo
41	An Analysis of Photoplethysmographic Signal in Diagnostic Lumbar Sympathetic Block for Complex Regional Pain Syndrome	Unknown status	NCT01134289	Phase 3
42	CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zoledronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)	Unknown status	NCT02504008	Phase 3	AXS-02 (oral zoledronate);Placebo
43	Surgical Treatment of Complex Regional Pain Syndrome Type II (CRPS II) by Regional Subcutaneous Venous Sympathectomy	Unknown status	NCT01392599	Phase 3
44	The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period	Unknown status	NCT02858453	Phase 3	AQX-1125 100 mg;AQX-1125 200 mg;Placebo
45	Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study	Unknown status	NCT03629769	Phase 3	Proxelan
46	Comparison of Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles in the Management of Myofascial Pain Disorder: A Randomized Clinical Trial	Completed	NCT03223298	Phase 3	Botulinum toxin type A;0.9% Sodium Chloride Injection
47	A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome	Completed	NCT01008553	Phase 3	Fentanyl;Placebo
48	Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I	Completed	NCT00817128	Phase 2, Phase 3
49	Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)	Completed	NCT02972359	Phase 3	Neridronic acid
50	A Multicenter, Double Blind, Randomised, Parallel Study to Assess Efficacy and Tolerability After Single Administration of Ketoprofen Lysine Salt 40 mg Granules vs Placebo in Subjects With Acute Pain Syndrome After Removal of Molar Teeth	Completed	NCT03836807	Phase 3	Ketoprofen

Search NIH Clinical Center for Paine Syndrome

Sources

Genetic Tests for Paine Syndrome

Sources

Anatomical Context for Paine Syndrome

Organs/tissues related to Paine Syndrome:

MalaCards : Dorsal Root Ganglion, Spinal Cord, Breast, Cortex, Brain, Prostate, Bone

Sources

Publications for Paine Syndrome

Articles related to Paine Syndrome:

(show top 50) (show all 14101)

#	Title	Authors	PMID	Year
1	X-chromosomal recessive microcephaly with epilepsy, spastic tetraplegia and absent abdominal reflexes. New variety of "Paine syndrome"? ⁶² ⁵⁷	Seemanova E...Proskova M	4274173	1973
2	Conference report: International Workshop on the fragile X and X-linked mental retardation. ⁵⁷	Opitz JM...Sutherland GR	6369987	1984
3	Evaluation of familial biochemically determined mental retardation in children, with special reference to aminoaciduria. ⁵⁷	PAINE RS	14429829	1960
4	Perioperative transcutaneous electrical acupoint stimulation (pTEAS) in pain management in major spinal surgery patients. ⁴¹	Wu X...Li Y	36348477	2022
5	Predictive Models for Knee Pain in Middle-Aged and Elderly Individuals Based on Machine Learning Methods. ⁴¹	Liu L...Zhang X	36199766	2022
6	Proposal and Efficacy of a Nurse-Led Pain Management Model for Neurointensive Care Based on the Precede-Proceed Model. ⁴¹	Zhu X...Jin M	35979046	2022
7	Pathophysiology and Clinical Biomarkers in Interstitial Cystitis. ⁶²	Masterson JM...Kim J	36424082	2023
8	Research progress and challenges of TRPV1 channel modulators as a prospective therapy for diabetic neuropathic pain. ⁶²	Liu C...Tian X	36395649	2023
9	Trigeminal Neuralgia. ⁶²	Khawaja SN...Scrivani SJ	36404084	2023
10	Persistent Idiopathic Dentoalveolar Pain: Is It a Central Pain Disorder? ⁶²	Heir GM...Renton T	36404082	2023
11	Peroxinitrite and Malondialdehyde as Biomarkers for Overactive Bladder. ⁶²	Sagir S...Ulusal H	36474380	2022
12	Reduced mastication is a risk factor for Rome IV postprandial distress syndrome in patients investigated with upper endoscopy. ⁶²	Pauletti RN...Fornari F	36244614	2022
13	Identifying female responders to proximal control exercises in patellofemoral pain syndrome: A clinical prediction rule. ⁶²	ElMelhat AM...Mohamed NA	36212592	2022
14	A postural program to reduce dynamic knee valgus during single-limb squatting in young athletes: a preliminary study. ⁶²	Sabina S...Canali V	35191290	2022
15	Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Letter. ⁶²	Hanno P	36129382	2022
16	Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Reply. ⁶²	Clemens JQ...Lai HH	36129383	2022
17	A Diagnostic Prediction Model for Separating Juvenile Idiopathic Arthritis and Chronic Musculoskeletal Pain Syndrome. ⁶²	van Straalen JW...Swart JF	35460700	2022
18	Efficacy of low-level laser therapy on pain, disability, pressure pain threshold, and range of motion in patients with myofascial neck pain syndrome: a systematic review and meta-analysis of randomized controlled trials. ⁶²	Tehrani MR...Sahebalam M	35962884	2022
19	Efficacy and safety of selective serotonin re-uptake inhibitors for chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis. ⁶²	Lao Y...Dong Z	35739025	2022
20	[Electrotherapeutical stellate ganglion block on a patient with complex regional pain syndrome of the upper limb]. ⁶²	Ranker A...Behr-Eggers E	36459205	2022
21	Personalised rehabilitation to improve return to work in patients with persistent spinal pain syndrome type II after spinal cord stimulation implantation: a study protocol for a 12-month randomised controlled trial-the OPERA study. ⁶²	Moens M...De Smedt A	36471349	2022
22	Transvaginal Photobiomodulation Improves Pain in Women with Pelvic Muscle Tenderness and Interstitial Cystitis/Bladder Pain Syndrome: A Preliminary Observational Study. ⁶²	Butrick CW...Lamvu G	36116559	2022
23	Predictors of Male Sexual Dysfunction in Urologic Chronic Pelvic Pain Syndrome (UCPPS), Other Chronic Pain Syndromes, and Healthy Controls in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. ⁶²	Loh-Doyle JC...Rodriguez LV	36180370	2022
24	Effect of electroacupuncture on inflammatory signal expression in local tissues of rats with chronic pelvic pain syndrome based on purinergic 2X7 receptor/NOD-like receptor pyrin domain-containing 3 signal pathway. ⁶²	Chang XU...Kai C	36378055	2022
25	Potential Role of Insulin-Like Growth Factors in Myofascial Pain Syndrome: A Narrative Review. ⁶²	Grosman-Rimon L...Eilat-Adar S	35067552	2022
26	Successful Multimodal Treatment for Complex Regional Pain Syndrome in an Adolescent with Acute Lymphoblastic Leukemia: A Case Report. ⁶²	Meeks H...Frett MJ	34936831	2022
27	Autoantibodies from patients with complex regional pain syndrome induce pro-inflammatory effects and functional disturbances on endothelial cells in vitro. ⁶²	Dharmalingam B...Tschernatsch M	35384930	2022
28	Nociception level index variations in patients with complex regional pain syndrome: a pilot study. ⁶²	Santella TM...Brulotte V	35260985	2022
29	Vaginal Hormone Therapy for Conditions of the Lower Urinary Tract. ⁶²	Nemirovsky A...Malik RD	36454371	2022
30	External snapping hip syndrome is associated with an increased femoral offset. ⁶²	Andronic O...Zingg PO	34550475	2022
31	[Less invasive turn-down flap tendinoplasty in chronic Achilles tendon rupture]. ⁶²	Amlang MH...Rammelt S	36036248	2022
32	The epidemiology of dystonia: the Hannover epidemiology study. ⁶²	Dressler D...Adib Saberi F	35948800	2022
33	Connective tissue graft versus xenogeneic collagen matrix for soft tissue augmentation at implant sites: a randomized-controlled clinical trial. ⁶²	Ashurko I...Corbella S	36029335	2022
34	Centralized nociplastic pain causing fibromyalgia: an emperor with no cloths? ⁶²	Martinez-Lavin M	36239845	2022
35	Chronic Pain Considerations in Patients with Cardiovascular Disease. ⁶²	Layne-Stuart CM...Carpenter AL	36328629	2022
36	[Surgical treatment of calcifying insertional Achilles tendinopathy via a lateral approach]. ⁶²	Amlang MH...Rammelt S	36342529	2022
37	Techniques for Safe Removal of Spinal Cord Stimulation Paddle Leads. ⁶²	Topp G...Pilitsis JG	36227247	2022
38	Diagnosis and treatment of pudendal and inferior cluneal nerve entrapment syndrome: a narrative review. ⁶²	Jottard K...de Wachter S	36074049	2022
39	Endoscopic treatment of gluteus medius tendon tear. ⁶²	Thaunat M...Francophone Arthroscopy Society (SFA)	36075568	2022
40	Neuromodulation for Management of Chronic Pelvic Pain: A Comprehensive Review. ⁶²	Hao D...Orhurhu V	36109459	2022
41	Effect of CYP2C9, PTGS-1 and PTGS-2 gene polymorphisms on the efficiency and safety of postoperative analgesia with ketoprofen. ⁶²	Sychev DA...Ryzhikova KA	35705023	2022
42	Intravenous Lidocaine in Chronic Neuropathic Pain: A Systematic Review. ⁶²	Lee JH...Argoff CE	36288104	2022
43	The Language of Pain: Is There a Relationship Between Metaphor Use and Adjustment to Chronic Pain? ⁶²	Munday I...Newton-John T	33729513	2022
44	Long-term Outcomes in Use of Opioids, Nonpharmacologic Pain Interventions, and Total Costs of Spinal Cord Stimulators Compared With Conventional Medical Therapy for Chronic Pain. ⁶²	Dhruva SS...Cohen K	36441532	2022
45	The first-generation anatomical medial meniscus prosthesis led to unsatisfactory results: a first-in-human study. ⁶²	van Tienen TG...Heesterbeek PJC	36336744	2022
46	A Comparison Between Rome III and Rome IV Criteria in Children with Chronic Abdominal Pain: A Prospective Observational Cohort Study. ⁶²	Demiroren K...Ekici D	35946891	2022
47	Coronary microvascular dysfunction affects left ventricular global longitudinal strain response to dipyridamole stress echocardiography: a pilot study. ⁶²	Tagliamonte E...D'Andrea A	36380229	2022
48	A novel distractor-assisted reduction combined with the sinus tarsi approach for joint depression-type calcaneal fractures. ⁶²	Zhang H...Jie K	36370163	2022
49	Natural History of Degenerative Hip Abductor Tendon Lesions. ⁶²	Schenk P...Zingg PO	36412545	2022
50	Prevalence and associated risk factors of tinnitus among adult Palestinians: a cross-sectional study. ⁶²	Al-Lahham S...Ellahham N	36450754	2022

Sources

Genes for Paine Syndrome

Genes related to Paine Syndrome (2 elite genes):

(show all 49)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HFE	Homeostatic Iron Regulator	Protein Coding	400	Pathogenic ⁵
2	PTPRQ	Protein Tyrosine Phosphatase Receptor Type Q	Protein Coding	400	Pathogenic ⁵
3	SCN4A	Sodium Voltage-Gated Channel Alpha Subunit 4	Protein Coding	31.32	Likely pathogenic ⁵ DISEASES inferred ¹⁴
4	COL5A1	Collagen Type V Alpha 1 Chain	Protein Coding	28.08	Likely pathogenic ⁵ DISEASES inferred ¹⁴
5	GJB1	Gap Junction Protein Beta 1	Protein Coding	25	Likely pathogenic ⁵
6	OAT	Ornithine Aminotransferase	Protein Coding	25	Likely pathogenic ⁵
7	MSD	Microcephaly With Spastic Diplegia (Paine Syndrome)	Genetic Locus	17.01	GeneCards inferred via : Publications Gene name (show sections)
8	PNOC	Prepronociceptin	Protein Coding	9.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12217418
9	GAL	Galanin And GMAP Prepropeptide	Protein Coding	8.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15615535 1380624
10	SCN9A	Sodium Voltage-Gated Channel Alpha Subunit 9	Protein Coding	8.67	DISEASES inferred ¹⁴
11	TRPV1	Transient Receptor Potential Cation Channel Subfamily V Member 1	Protein Coding	8.06	DISEASES inferred ¹⁴
12	SCN11A	Sodium Voltage-Gated Channel Alpha Subunit 11	Protein Coding	7.95	DISEASES inferred ¹⁴
13	TAC1	Tachykinin Precursor 1	Protein Coding	7.92	DISEASES inferred ¹⁴
14	SCN10A	Sodium Voltage-Gated Channel Alpha Subunit 10	Protein Coding	7.83	DISEASES inferred ¹⁴
15	NGF	Nerve Growth Factor	Protein Coding	7.68	DISEASES inferred ¹⁴
16	TRPA1	Transient Receptor Potential Cation Channel Subfamily A Member 1	Protein Coding	7.44	DISEASES inferred ¹⁴
17	P2RX3	Purinergic Receptor P2X 3	Protein Coding	7.27	DISEASES inferred ¹⁴
18	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	7.22	DISEASES inferred ¹⁴
19	SCN3A	Sodium Voltage-Gated Channel Alpha Subunit 3	Protein Coding	7.02	DISEASES inferred ¹⁴
20	OPRM1	Opioid Receptor Mu 1	Protein Coding	6.94	DISEASES inferred ¹⁴
21	LAPTM4A	Lysosomal Protein Transmembrane 4 Alpha	Protein Coding	6.91	DISEASES inferred ¹⁴
22	TRPM8	Transient Receptor Potential Cation Channel Subfamily M Member 8	Protein Coding	6.86	DISEASES inferred ¹⁴
23	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	6.82	DISEASES inferred ¹⁴
24	SCN1A	Sodium Voltage-Gated Channel Alpha Subunit 1	Protein Coding	6.78	DISEASES inferred ¹⁴
25	SCN8A	Sodium Voltage-Gated Channel Alpha Subunit 8	Protein Coding	6.77	DISEASES inferred ¹⁴
26	H2AC18	H2A Clustered Histone 18	Protein Coding	6.74	DISEASES inferred ¹⁴ ¹⁴
27	IL1B	Interleukin 1 Beta	Protein Coding	6.74	DISEASES inferred ¹⁴
28	IL6	Interleukin 6	Protein Coding	6.7	DISEASES inferred ¹⁴
29	MIR548D1	MicroRNA 548d-1	RNA Gene	6.69	DISEASES inferred ¹⁴ ¹⁴
30	COMT	Catechol-O-Methyltransferase	Protein Coding	6.62	DISEASES inferred ¹⁴
31	TNF	Tumor Necrosis Factor	Protein Coding	6.58	DISEASES inferred ¹⁴
32	TACR1	Tachykinin Receptor 1	Protein Coding	6.54	DISEASES inferred ¹⁴
33	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	6.48	DISEASES inferred ¹⁴
34	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	6.48	DISEASES inferred ¹⁴
35	NAV1	Neuron Navigator 1	Protein Coding	6.44	DISEASES inferred ¹⁴
36	TRPV4	Transient Receptor Potential Cation Channel Subfamily V Member 4	Protein Coding	6.43	DISEASES inferred ¹⁴
37	KNG1	Kininogen 1	Protein Coding	6.41	DISEASES inferred ¹⁴
38	ASIC3	Acid Sensing Ion Channel Subunit 3	Protein Coding	6.4	DISEASES inferred ¹⁴
39	FOS	Fos Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	6.22	DISEASES inferred ¹⁴
40	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	6.19	DISEASES inferred ¹⁴
41	P2RX4	Purinergic Receptor P2X 4	Protein Coding	6.17	DISEASES inferred ¹⁴
42	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	6.15	DISEASES inferred ¹⁴
43	CRH	Corticotropin Releasing Hormone	Protein Coding	6.12	DISEASES inferred ¹⁴
44	P2RX2	Purinergic Receptor P2X 2	Protein Coding	6.09	DISEASES inferred ¹⁴
45	SCN2A	Sodium Voltage-Gated Channel Alpha Subunit 2	Protein Coding	6.05	DISEASES inferred ¹⁴
46	KCNK18	Potassium Two Pore Domain Channel Subfamily K Member 18	Protein Coding	6.04	DISEASES inferred ¹⁴
47	SCN5A	Sodium Voltage-Gated Channel Alpha Subunit 5	Protein Coding	6.03	DISEASES inferred ¹⁴
48	POMC	Proopiomelanocortin	Protein Coding	6.02	DISEASES inferred ¹⁴
49	IL10	Interleukin 10	Protein Coding	6	DISEASES inferred ¹⁴

Sources

Variations for Paine Syndrome

ClinVar genetic disease variations for Paine Syndrome:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	HFE	NM_000410.4(HFE):c.845G>A (p.Cys282Tyr)	SNV	Pathogenic	9	rs1800562	GRCh37: 6:26093141-26093141 GRCh38: 6:26092913-26092913
2	PTPRQ	NM_001145026.2(PTPRQ):c.6475C>T (p.Arg2159Ter)	SNV	Pathogenic	523416	rs1445287184	GRCh37: 12:81064144-81064144 GRCh38: 12:80670365-80670365
3	COL5A1	NM_000093.5(COL5A1):c.608G>T (p.Gly203Val)	SNV	Likely Pathogenic	523328	rs1554781700	GRCh37: 9:137593133-137593133 GRCh38: 9:134701287-134701287
4	OAT	NM_000274.4(OAT):c.875A>G (p.Lys292Arg)	SNV	Likely Pathogenic	374146	rs1057518927	GRCh37: 10:126091521-126091521 GRCh38: 10:124402952-124402952
5	SCN4A	NM_000334.4(SCN4A):c.1333G>T (p.Val445Leu)	SNV	Likely Pathogenic	373945	rs121908552	GRCh37: 17:62041947-62041947 GRCh38: 17:63964587-63964587
6	GJB1	NM_000166.6(GJB1):c.109G>T (p.Val37Leu)	SNV	Likely Pathogenic	374173	rs1057518946	GRCh37: X:70443666-70443666 GRCh38: X:71223816-71223816
7	SELENON	NM_020451.3(SELENON):c.482G>A (p.Arg161Gln)	SNV	Uncertain Significance	373919	rs765749301	GRCh37: 1:26131711-26131711 GRCh38: 1:25805220-25805220
8	KIF1B	NM_001365951.3(KIF1B):c.2611G>A (p.Glu871Lys)	SNV	Uncertain Significance	373920	rs763122049	GRCh37: 1:10384889-10384889 GRCh38: 1:10324831-10324831
9	MAP2K2	NM_030662.4(MAP2K2):c.514A>G (p.Lys172Glu)	SNV	Uncertain Significance	523536	rs1413580671	GRCh37: 19:4102388-4102388 GRCh38: 19:4102390-4102390

Sources

Expression for Paine Syndrome

Search GEO for disease gene expression data for Paine Syndrome.

Sources

Pathways for Paine Syndrome

Pathways related to Paine Syndrome according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cardiac conduction ⁶⁶ Show member pathways Classical Kir channels ⁶⁶ Ion homeostasis ⁶⁶ Ion transport by P-type ATPases ⁶⁶ Muscle contraction ⁶⁶ Phase 1 - inactivation of fast Na+ channels ⁶⁶ Phase 2 - plateau phase ⁶⁶ Phase 3 - rapid repolarisation ⁶⁶ Phase 4 - resting membrane potential ⁶⁶ Physiological factors ⁶⁶ Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) ⁶⁶ Tandem pore domain halothane-inhibited K+ channel (THIK) ⁶⁶ Tandem pore domain potassium channels ⁶⁶ TWIK related potassium channel (TREK) ⁶⁶ TWIK-related alkaline pH activated K+ channel (TALK) ⁶⁶ TWIK-related spinal cord K+ channel (TRESK) ⁶⁶ TWIK-releated acid-sensitive K+ channel (TASK) ⁶⁶	12.56	SCN9A SCN4A SCN3A SCN11A SCN10A
2	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.39	SCN9A SCN4A SCN3A SCN11A SCN10A
3	Neuropathic Pain-Signaling in Dorsal Horn Neurons ⁶⁴ Show member pathways Aldosterone Signaling in Epithelial Cells ⁶⁴ Cholera Infection ⁶⁴	12.39	TAC1 SCN9A SCN4A SCN3A SCN11A SCN10A
4	Neuroscience ³	12.23	SCN9A SCN4A SCN11A SCN10A OPRM1 NGF
5	L1CAM interactions ⁶⁶ Show member pathways CHL1 interactions ⁶⁶ Neurofascin interactions ⁶⁶ NrCAM interactions ⁶⁶ Recycling pathway of L1 ⁶⁶	11.93	SCN9A SCN4A SCN3A SCN11A SCN10A
6	Phase 0 - rapid depolarisation ⁶⁶	10.89	SCN9A SCN4A SCN3A SCN11A SCN10A
7	Interaction between L1 and Ankyrins ⁶⁶	10.51	SCN9A SCN4A SCN3A SCN11A SCN10A
8	Chronic hyperglycemia impairment of neuron function ⁷⁴	9.85	TRPV1 TRPA1

Sources

GO Terms for Paine Syndrome

Cellular components related to Paine Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016021	10.48	TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
2	membrane	GO:0016020	10.48	TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
3	plasma membrane	GO:0005887	10.34	HFE OPRM1 P2RX3 SCN4A SCN9A TRPA1
4	plasma membrane	GO:0005886	10.34	HFE OPRM1 P2RX3 SCN4A SCN9A TRPA1
5	neuronal cell body	GO:0043025	9.97	TRPV1 TAC1 SCN11A PNOC P2RX3 GAL
6	voltage-gated sodium channel complex	GO:0001518	9.65	SCN10A SCN11A SCN3A SCN4A SCN9A
7	stereocilium bundle	GO:0032421	9.58	TRPA1 PTPRQ
8	axon	GO:0030424	9.58	TAC1 SCN9A SCN4A SCN3A SCN11A SCN10A
9	obsolete integral component of presynaptic membrane	GO:0099056	9.43	SCN10A P2RX3 OPRM1

Biological processes related to Paine Syndrome according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of monoatomic ion transmembrane transport	GO:0034765	10.27	SCN10A SCN11A SCN3A SCN4A SCN9A
2	sodium ion transmembrane transport	GO:0035725	10.25	SCN9A SCN4A SCN3A SCN11A SCN10A
3	neuropeptide signaling pathway	GO:0007218	10.24	CALCA GAL OPRM1 PNOC TAC1
4	sodium ion transport	GO:0006814	10.18	SCN9A SCN4A SCN3A SCN11A SCN10A
5	positive regulation of cytosolic calcium ion concentration	GO:0007204	10.17	TRPV1 TAC1 OPRM1 CALCA
6	transmembrane transport	GO:0055085	10.16	GJB1 SCN10A SCN11A SCN3A SCN4A SCN9A
7	calcium ion transmembrane transport	GO:0070588	10.15	OPRM1 SCN11A TRPA1 TRPV1
8	response to cold	GO:0009409	10.09	TRPA1 SCN9A P2RX3
9	cellular response to nerve growth factor stimulus	GO:1990090	10.07	TRPV1 TAC1 CALCA
10	sensory perception	GO:0007600	10.03	SCN10A PNOC OPRM1
11	response to heat	GO:0009408	10.03	CALCA P2RX3 SCN11A SCN9A TRPV1
12	monoatomic ion transport	GO:0006811	9.96	TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
13	response to pain	GO:0048265	9.95	TRPV1 TRPA1 TAC1 CALCA
14	detection of temperature stimulus involved in sensory perception of pain	GO:0050965	9.93	TRPV1 SCN9A SCN11A CALCA
15	thermoception	GO:0050955	9.9	TRPV1 TRPA1
16	sensory perception of pain	GO:0019233	9.9	OPRM1 SCN10A SCN9A TAC1 TRPA1 TRPV1
17	monoatomic cation transmembrane transport	GO:0098655	9.89	SCN9A SCN3A SCN11A SCN10A P2RX3
18	detection of chemical stimulus involved in sensory perception of pain	GO:0050968	9.88	TRPV1 TRPA1
19	behavioral response to formalin induced pain	GO:0061368	9.88	SCN9A SCN11A P2RX3
20	monoatomic ion transmembrane transport	GO:0034220	9.87	P2RX3 SCN10A SCN11A SCN3A SCN9A TRPA1
21	urinary bladder smooth muscle contraction	GO:0014832	9.79	TRPV1 P2RX3
22	behavioral response to pain	GO:0048266	9.77	TRPV1 SCN9A SCN3A P2RX3
23	membrane depolarization during action potential	GO:0086010	9.65	SCN9A SCN4A SCN3A SCN11A SCN10A
24	calcitonin gene-related peptide receptor signaling pathway	GO:1990408	9.58	SCN11A CALCA
25	neuronal action potential	GO:0019228	9.4	SCN9A SCN4A SCN3A SCN11A SCN10A P2RX3

Molecular functions related to Paine Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	voltage-gated monoatomic ion channel activity	GO:0005244	9.97	SCN9A SCN4A SCN3A SCN11A SCN10A
2	voltage-gated sodium channel activity	GO:0005248	9.96	SCN10A SCN11A SCN3A SCN4A SCN9A
3	calcium-release channel activity	GO:0015278	9.67	TRPV1 TRPA1
4	sodium channel activity	GO:0005272	9.55	SCN9A SCN4A SCN3A SCN11A SCN10A
5	monoatomic cation channel activity	GO:0005261	9.43	TRPV1 SCN9A SCN4A SCN3A SCN11A SCN10A
6	monoatomic ion channel activity	GO:0005216	9.28	TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A